Search results
3 days ago · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global threat, causing severe respiratory illness and fatalities. 1,2 Phylogenetically related to the 2003 SARS-CoV epidemic, 3 ...
5 days ago · In 2020, the novel coronavirus, known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the causative agent of COVID-19 (coronavirus disease 2019), precipitated one of the most ...
1 day ago · Abstract. The 800 million human infections with SARS-CoV-2 and the likely emergence of new variantsand additional coronaviruses necessitate a better understanding of the essential spikeglycoprotein and the development of immunogens that foster broader and more durable immunity.The S2 fusion subunit is more conserved in sequence, is essential to function, and would be adesirable immunogen to ...
4 days ago · Although the emergency has ended, the pandemic has not, and COVID-19 is currently causing ∼ 1,000 deaths per week in the United States. 1 If this is the endemic pace of mortality from SARS-CoV-2, it will add to 12,000–52,000 deaths from influenza per year, more than doubling the total of deaths caused by respiratory viruses. 2 SARS-CoV-2 ...
4 days ago · RSLV-132 is a biologic drug composed of catalytically active human RNase1 fused to human IgG1 Fc and is designed to remain in circulation and digest extracellular RNA. We hypothesized that removal of SARS-CoV-2 viral RNA from latent reservoirs may improve inflammation, neuroinflammation, and fatigue associated with post-acute sequelae of SARS ...
3 days ago · Neutralizing antibodies targeting the spike (S) protein of SARS-CoV-2, elicited either by natural infection or vaccination, are crucial for protection against the virus. Nonetheless, the emergence of viral escape mutants presents ongoing challenges by contributing to breakthrough infections. To define the evolution trajectory of SARS-CoV-2 within the immune population, we co-incubated ...
5 days ago · A University of Alberta research team has uncovered a new class of drugs with the potential to prevent or treat infections in a future viral outbreak. In research newly published in npj Viruses, the team reports that SARS-CoV-2, the virus that causes COVID-19, activates a pathway in cells that stops the production of peroxisomes and interferon ...
